The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia

[1] Andriani GA(2016)Whole chromosome instability induces senescence and promotes SASP Sci Rep 6 35218-1322

[2] Almeida VP(2011)Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation Blood 118 1316-1579

[3] Faggioli F(2018)Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia Blood Adv 2 1572-9

[4] Augereau A(1999)Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia Am J Hematol 61 5-2039

[5] de T’kint RC(2014)A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells Leukemia 28 2028-790

[6] Simonet T(2014)Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy Cell Stem Cell 15 775-1890

[7] Bouillon A-S(2000)Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry Blood 95 1883-1773

[8] Ventura Ferreira MS(2017)Decoding telomere protein Rap 1: Its telomeric and nontelomeric functions and potential implications in diabetic cardiomyopathy Cell Cycle 16 1765-679

[9] Awad SA(2006)hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia Leukemia 20 671-247

[10] Boultwood J(2018)Shelterin-mediated telomere protection Annu Rev Genet 52 223-1781

[1] Andriani GA(2016)Whole chromosome instability induces senescence and promotes SASP Sci Rep 6 35218-1322

[2] Almeida VP(2011)Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation Blood 118 1316-1579

[3] Faggioli F(2018)Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia Blood Adv 2 1572-9

[4] Augereau A(1999)Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia Am J Hematol 61 5-2039

[5] de T’kint RC(2014)A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells Leukemia 28 2028-790

[6] Simonet T(2014)Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy Cell Stem Cell 15 775-1890

[7] Bouillon A-S(2000)Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry Blood 95 1883-1773

[8] Ventura Ferreira MS(2017)Decoding telomere protein Rap 1: Its telomeric and nontelomeric functions and potential implications in diabetic cardiomyopathy Cell Cycle 16 1765-679

[9] Awad SA(2006)hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia Leukemia 20 671-247

[10] Boultwood J(2018)Shelterin-mediated telomere protection Annu Rev Genet 52 223-1781